ArticleNeurology and therapy2021

Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.

Edward E Neuberger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.